Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: betty moyers who wrote (18351)	1/29/1999 1:53:00 PM
From: Mkilloran	Respond to of 23519

betty...I believe you will see domestic earnings of about $5.6 mill in the 1st qtr. without any increase in scripts sales. Vivus has depleted the domestic backlog and the ims weekly script numbers do not capture all sales. What were dealing with here is how much Vivus will ship in the 1st qtr. As you noted 3rd qtr income was 3.4 mill 4th qtr was 4.8 mill these two numbers relate to shipped product of aprox 2800 scripts a week in the 3rd qtr and 3900 scripts a week in the 4th qtr. Now if inventories are low and vivus ships about 4500 scripts a week in the 1st qtr 99 they would book 5.6 mill VA sales and direct sales to group health providers are not captured in the IMS weekly sales script counts...so we could see more than 4500 scripts a week shiped. Now if we see script counts going higher all for the better.